Clinical Trial Search

Primary: Confirmed Response Rate — 0.06 proportion of patients

Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants

Primary: Response to Therapy — 10; 2 Participants

Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)

Primary: Percentage of Patients Achieving at Least 2 x 10^6 Cluster of Differentiation 34 (CD34) Cells Per Kg Recipient Body Weight on Day 1 of Apheresis — 98 percentage of…

Primary: Number of Participants With Complete Response (CR) — 14 participants

Primary: Number of Patients With Complete Response — 14; 3 participants

Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…

Primary: Number of Participants With Hematologic Response — 7 participants

Primary: Response Rate — 0; 1; 3; 11 Participants

Primary: Number of Participants Who Achieved a Confirmed Response Defined as a Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) — 21 participants

Primary: Maximum Tolerated Dose (MTD) of PGG Beta Glucan in Combination With Alemtuzumab and Rituximab Assessed by Analyzing the Number of Dose-limiting Toxicity Events (Phase I)…

Primary: Median Progression Free Survival (mPFS) — 76.4 months

Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Hematologic Response Rate — 55.9; 69.1 percentage of participants

Primary: Complete Hematologic Response — 16 participants

Primary: Hematologic and Organ Response — 11; 7; 18 participants

Primary: Number of Participants With Adverse Events in All Subjects — 11 Participants

Primary: Overall Objective Response — 10; 5; 26; 4 Participants

Primary: Response Rate — 55.2 percentage

Primary: Number of Participants With a Confirmed Hematologic Response — 0; 0; 0 participants

Primary: International Myeloma Working Group (IMWG) Response Criteria — 8; 4; 7; 19 participants

Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS

Primary: Number of Subjects With Adverse Events — 199 Participants

Primary: Overall Survival (OS) — 40 months

Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants

Primary: Complete Response Rate — 10 percentage of participants

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 116; 11 Participants

Primary: Number of Subjects Treated With (HD DTPACE Obtain a Complete Response or Near Complete Response That Lasts for 6 Months or Longer. — 0 participant response